• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by KALA BIO Inc.

    11/14/25 4:01:05 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALA alert in real time by email
    NT 10-Q 1 kala-20250930xnt10q.htm NT 10-Q

    ​

    ​

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 12b-25

    Commission File No. 001-38150

    ​

    NOTIFICATION OF LATE FILING

    ​

    (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N- CSR

    ​

    For Period Ended: September 30, 2025

    ​

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

    ​

    For the Transition Period Ended:

    ​

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

    ​

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

    ​

    PART I - REGISTRANT INFORMATION

    ​

    KALA BIO, Inc.

    Full name of registrant

    ​

    Not Applicable

    Former name if applicable

    ​

    1167 Massachusetts Avenue

    Address of principal executive office (Street and Number)

    ​

    Arlington, MA 02476

    City, state and zip code

    ​

    PART II - RULES 12b-25(b) AND (c)

    ​

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

    ​

    (a)

    The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

    ​

    ☒   (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N- CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

    ​


    (c)The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    ​

    PART III - NARRATIVE

    KALA BIO, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense.

    As previously disclosed, on September 29, 2025, the Company received a written notice (the “Notice”) of event of default from Oxford Finance LLC (“Oxford”) with respect to the Loan and Security Agreement, dated as of May 4, 2021 (as amended, the “Loan Agreement”), by and among the Company, Combangio, Inc. and Oxford, as lender and collateral agent. In the Notice, Oxford declared, by reason of the event of default, that all obligations of the Company under the Loan Agreement were immediately due and payable. On October 19, 2025, pursuant to the terms of the Loan Agreement, Oxford informed the Company that it intended to foreclose on all of the Company’s remaining assets and that Oxford would not consent to the Company’s use of cash for any reason other than for minimal payroll and related expenses pending Oxford’s foreclosure of the Company’s assets. In addition, Oxford swept substantially all of the Company’s cash resources from its bank accounts. As a result, on October 19, 2025, the Board of Directors of the Company terminated all remaining employees not deemed necessary by Oxford to execute a foreclosure of the Company’s assets. The Company was therefore unable to pay employees, external advisors or the Company’s independent registered public accounting firm to assist in the preparation and timely filing of the Form 10-Q.

    On November 3, 2025, Oxford informed the Company that it intended to pause its foreclosure of the Company’s assets and permitted the Company to use $125,000 of cash it previously swept to fund the negotiation and execution of the Convertible Loan Agreement (as defined below) and preliminary preparation work on the Form 10-Q.

    On November 9, 2025, the Company entered into a Convertible Loan Agreement (the “Convertible Loan Agreement”) with an individual investor (the “Lender”) pursuant to which the Lender agreed to provide the Company a convertible loan in the aggregate amount of up to $375,000. Pursuant to the terms of the Convertible Loan Agreement, the Company is permitted to use a portion of the proceeds of the Convertible Loan Agreement for the preparation and filing of the Form 10-Q.

    Due to the reasons described above, the Company could not have timely filed the Form 10-Q without unreasonable effort or expense, and the Form 10-Q will be filed no later than the fifth calendar day following the prescribed due date.

    PART IV - OTHER INFORMATION

    (1)

    Name and telephone number of person to contact in regard to this notification.

    ​

    Mary Reumuth

        

    (781)

        

    996-5252

    (Name)

    ​

    (Area Code)

    ​

    (Telephone Number)

    ​

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

    ​

    ☒ Yes ☐ No

    ​

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

    ​

    ☐ Yes ☒ No

    ​

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

    ​

    Not applicable.

    ​

    ​

    ​


    KALA BIO, Inc.

    (Name of Registrant as Specified in Charter)

    Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

    ​

    Date: November 14, 2025

    By:

    /s/ Mary Reumuth

    ​

    ​

    Mary Reumuth

    ​

    ​

    Chief Financial Officer and Corporate Secretary

    ​

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

    ATTENTION

     

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

    ​

    Cautionary Note Regarding Forward-Looking Statements

    Statements contained in this Form 12b-25 regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s plans to file the Form 10-Q on the anticipated timeline and Oxford’s plans to foreclose on the Company’s assets. Any forward-looking statements in this Form 12b-25 are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, the Company’s ability to continue to operate; uncertainty as to the result and timing of the Oxford foreclosure process; the Company’s ability to successfully obtain additional financing; the Company’s ability to identify and consummate a strategic transaction and those other risks and uncertainties set forth in the Company’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025 and June 30, 2025, and in subsequent filings the Company may make with the SEC. All forward-looking statements contained in this Form 12b-25 speak only as of the date of this Form 12b-25. The Company anticipates that subsequent events and developments will cause its views to change. However, the Company undertakes no obligation to update such forward-looking statements to reflect events that occur or circumstances that exist after the date of this Form 12b-25, except as required by law.


    Get the next $KALA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KALA

    DatePrice TargetRatingAnalyst
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    9/29/2025Buy → Neutral
    H.C. Wainwright
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    9/8/2025$30.00Outperform
    Mizuho
    7/11/2025$12.00Buy
    Ladenburg Thalmann
    3/30/2022Neutral → Underweight
    JP Morgan
    8/6/2021$14.00 → $11.00Buy
    HC Wainwright & Co.
    8/6/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $KALA
    SEC Filings

    View All

    SEC Form 10-Q filed by KALA BIO Inc.

    10-Q - KALA BIO, Inc. (0001479419) (Filer)

    11/19/25 7:26:53 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by KALA BIO Inc.

    NT 10-Q - KALA BIO, Inc. (0001479419) (Filer)

    11/14/25 4:01:05 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by KALA BIO Inc.

    SCHEDULE 13G/A - KALA BIO, Inc. (0001479419) (Subject)

    11/14/25 4:00:03 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Reumuth Mary sold $27,544 worth of shares (33,197 units at $0.83), decreasing direct ownership by 53% to 28,906 units (SEC Form 4)

    4 - KALA BIO, Inc. (0001479419) (Issuer)

    10/24/25 8:00:12 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Iwicki Mark T sold $125,464 worth of shares (154,894 units at $0.81), decreasing direct ownership by 60% to 103,540 units (SEC Form 4)

    4 - KALA BIO, Inc. (0001479419) (Issuer)

    10/24/25 8:00:13 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Kharabi Darius sold $17,269 worth of shares (20,806 units at $0.83), decreasing direct ownership by 33% to 41,760 units (SEC Form 4)

    4 - KALA BIO, Inc. (0001479419) (Issuer)

    10/24/25 8:00:05 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

    -- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related serious adverse events observed -- -- KALA to cease clinical development of KPI-012, preserve cash and explore strategic options -- ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that its CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial of

    9/29/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

    ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY on Wednesday, September 10, 2025 at 2:00 p.m. ET. Management will be available for one-on-one meetings on Wednesday, September 10, 2025. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com. Abo

    9/3/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KALA BIO downgraded by Mizuho with a new price target

    Mizuho downgraded KALA BIO from Outperform to Neutral and set a new price target of $1.50

    9/30/25 9:48:28 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by H.C. Wainwright

    H.C. Wainwright downgraded KALA BIO from Buy to Neutral

    9/29/25 1:25:35 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded KALA BIO from Buy to Neutral

    9/29/25 9:48:46 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $2,000,000 worth of shares (310,559 units at $6.44) (SEC Form 4)

    4 - KALA BIO, Inc. (0001479419) (Issuer)

    12/31/24 4:00:18 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Financials

    Live finance-specific insights

    View All

    Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

    ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on August 30, 2022. The

    8/18/22 4:01:00 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    -- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and prov

    8/11/22 7:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

    ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651. To access a live webcast and subsequent archived recording of the call, please visit the "Presentations" se

    8/8/22 9:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Leadership Updates

    Live Leadership Updates

    View All

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Announces Chief Executive Officer Transition

    ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

    2/12/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

    -- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 ---- Received FDA Fast Track designation for KPI-012 for the treatment of PCED ---- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and sever

    5/9/23 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by KALA BIO Inc.

    SC 13G - KALA BIO, Inc. (0001479419) (Subject)

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by KALA BIO Inc.

    SC 13D - KALA BIO, Inc. (0001479419) (Subject)

    7/8/24 8:54:55 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by KALA BIO Inc.

    SC 13D - KALA BIO, Inc. (0001479419) (Subject)

    6/28/24 4:11:51 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care